China's H1N1 Flu Vaccine Said To Pass Phase I Trials
This article was originally published in PharmAsia News
Executive Summary
The Health Ministry in China declared its version of an H1N1 flu vaccine has passed Phase I trials showing it to be safe and efficacious. The vaccine already is being prepared for Phase II trials after the initial round turned up no severe adverse reactions among more than 13,000 volunteers. Health Minister Chen Zhu held a news conference to announce the results and received his second injection of the vaccine. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.